AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact
Ivonescimab is currently in development as a combination drug across several types of solid tumours.
Therapy Area
Novartis bets on autoimmune BiTEs through $7.8bn Abogen deal
Varda pockets $251m to back space-based pharma processing mission
EASD 2026: Tirzepatide outperforms semaglutide in real-world type 2 diabetes analysis
Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
EASD 2026: Orforglipron shows an efficacy edge over oral semaglutide in T2D
Daiichi Sankyo, MSD withdraw cancer drug application
FDA hearing: psychedelics launch needs balanced regulation without limiting access
